{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T17:54:39Z","timestamp":1781200479676,"version":"3.54.1"},"reference-count":37,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Chronic graft-versus-host disease (cGVHD) is the leading cause of long-term morbidity and mortality after allogeneic hematopoietic stem cell transplantation. We hypothesize that it is possible to decrease its risk by manipulating the immune response in late phases of transplantation. We performed a prospective randomized trial including 73 patients. Patients in the treatment arm received 4 mg of ixazomib (IXZ) every 28 days from day +100. With a median follow-up of 24 months, the cumulative incidence of moderate\/severe cGVHD in the IXZ vs control groups at 1 and 2 years were: 3.23% vs 30.2% (hazard ratio [HR], 0.089; P = .02) and 13% vs 43% (HR, 0.23; P = .01), respectively. Estimates for cGVHD and relapse-free survival at 2 years were 81% for IXZ and 49% for the control group (HR, 0.30). Increased STAT3 and p38 phosphorylation in T cells, and higher proportion of B cells that have undergone immunoglobulin isotype switching and circulating plasma cells on day +180 were associated with a significantly higher risk of developing moderate\/severe cGVHD. The administration of IXZ decreases the risk of moderate\/severe cGVHD. It is possible to identify biological patterns by flow cytometry to predict the risk of cGVHD. This trial was registered at www.clinicaltrials.gov as #NCT03225417.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016284","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T19:01:58Z","timestamp":1753902118000},"page":"5528-5538","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7487-3793","authenticated-orcid":false,"given":"Teresa","family":"Caballero-Vel\u00e1zquez","sequence":"first","affiliation":[{"name":"1Department of Hematology, University Hospital Virgen del Rocio, Instituto de Biomedicina de Sevilla\/Consejo Superior de Investigaciones Cient\u00edficas, Universidad de Sevilla, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Delgado Serrano","sequence":"additional","affiliation":[{"name":"1Department of Hematology, University Hospital Virgen del Rocio, Instituto de Biomedicina de Sevilla\/Consejo Superior de Investigaciones Cient\u00edficas, Universidad de Sevilla, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"L\u00f3pez-Corral","sequence":"additional","affiliation":[{"name":"2Hematology Department, Hospital Universitario de Salamanca (Spain), Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Oncolog\u00eda, Centro de Investigaci\u00f3n del C\u00e1ncer-Instituto de Biolog\u00eda Molecular y Celular del C\u00e1ncer (Universidad de Salamanca, Consejo Superior de Investigaciones Cient\u00edficas), Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4571-5125","authenticated-orcid":false,"given":"Christelle","family":"Ferra-Coll","sequence":"additional","affiliation":[{"name":"3Hematology Department, Hospital Germans Trias i Pujol, Institut Catal\u00e0 d'Oncologia Badalona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara Beatriz","family":"Garc\u00eda-Calder\u00f3n","sequence":"additional","affiliation":[{"name":"1Department of Hematology, University Hospital Virgen del Rocio, Instituto de Biomedicina de Sevilla\/Consejo Superior de Investigaciones Cient\u00edficas, Universidad de Sevilla, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Valc\u00e1rcel","sequence":"additional","affiliation":[{"name":"4Hematology Department, Vall d\u2019hebron Institut Oncologic, University Hospital Vall d\u2019hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Garc\u00eda-Cadenas","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Hospital de Sant Pau, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0732-3235","authenticated-orcid":false,"given":"Estefan\u00eda","family":"P\u00e9rez L\u00f3pez","sequence":"additional","affiliation":[{"name":"2Hematology Department, Hospital Universitario de Salamanca (Spain), Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Oncolog\u00eda, Centro de Investigaci\u00f3n del C\u00e1ncer-Instituto de Biolog\u00eda Molecular y Celular del C\u00e1ncer (Universidad de Salamanca, Consejo Superior de Investigaciones Cient\u00edficas), Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Jos\u00e9","family":"Jim\u00e9nez Lorenzo","sequence":"additional","affiliation":[{"name":"3Hematology Department, Hospital Germans Trias i Pujol, Institut Catal\u00e0 d'Oncologia Badalona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7536-8907","authenticated-orcid":false,"given":"Francisco Manuel","family":"Mart\u00edn-Dom\u00ednguez","sequence":"additional","affiliation":[{"name":"1Department of Hematology, University Hospital Virgen del Rocio, Instituto de Biomedicina de Sevilla\/Consejo Superior de Investigaciones Cient\u00edficas, Universidad de Sevilla, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2723-319X","authenticated-orcid":false,"given":"Mar\u00eda de los Reyes","family":"Jim\u00e9nez-Le\u00f3n","sequence":"additional","affiliation":[{"name":"1Department of Hematology, University Hospital Virgen del Rocio, Instituto de Biomedicina de Sevilla\/Consejo Superior de Investigaciones Cient\u00edficas, Universidad de Sevilla, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7889-5807","authenticated-orcid":false,"given":"Guillermo","family":"Orti","sequence":"additional","affiliation":[{"name":"4Hematology Department, Vall d\u2019hebron Institut Oncologic, University Hospital Vall d\u2019hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0639-574X","authenticated-orcid":false,"given":"Virginia","family":"Escamilla G\u00f3mez","sequence":"additional","affiliation":[{"name":"1Department of Hematology, University Hospital Virgen del Rocio, Instituto de Biomedicina de Sevilla\/Consejo Superior de Investigaciones Cient\u00edficas, Universidad de Sevilla, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Bl\u00e1zquez-Go\u00f1i","sequence":"additional","affiliation":[{"name":"1Department of Hematology, University Hospital Virgen del Rocio, Instituto de Biomedicina de Sevilla\/Consejo Superior de Investigaciones Cient\u00edficas, Universidad de Sevilla, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Cabero Mart\u00ednez","sequence":"additional","affiliation":[{"name":"2Hematology Department, Hospital Universitario de Salamanca (Spain), Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Oncolog\u00eda, Centro de Investigaci\u00f3n del C\u00e1ncer-Instituto de Biolog\u00eda Molecular y Celular del C\u00e1ncer (Universidad de Salamanca, Consejo Superior de Investigaciones Cient\u00edficas), Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5079-3420","authenticated-orcid":false,"given":"Henry","family":"Andrade Ruiz","sequence":"additional","affiliation":[{"name":"6Fundaci\u00f3n para la Gesti\u00f3n de la Investigaci\u00f3n en Salud en Sevilla, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefan\u00eda","family":"Men\u00e9ndez-Pedregal","sequence":"additional","affiliation":[{"name":"1Department of Hematology, University Hospital Virgen del Rocio, Instituto de Biomedicina de Sevilla\/Consejo Superior de Investigaciones Cient\u00edficas, Universidad de Sevilla, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferm\u00edn","family":"S\u00e1nchez-Guijo","sequence":"additional","affiliation":[{"name":"2Hematology Department, Hospital Universitario de Salamanca (Spain), Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Oncolog\u00eda, Centro de Investigaci\u00f3n del C\u00e1ncer-Instituto de Biolog\u00eda Molecular y Celular del C\u00e1ncer (Universidad de Salamanca, Consejo Superior de Investigaciones Cient\u00edficas), Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"P\u00e9rez Sim\u00f3n","sequence":"additional","affiliation":[{"name":"1Department of Hematology, University Hospital Virgen del Rocio, Instituto de Biomedicina de Sevilla\/Consejo Superior de Investigaciones Cient\u00edficas, Universidad de Sevilla, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"2025111014271243000_bib1","first-page":"146","volume-title":"Thomas' Hematopoietic Cell Transplantation","author":"Ferrara","year":"2016","edition":"5th ed"},{"key":"2025111014271243000_bib2","doi-asserted-by":"publisher","first-page":"100792","DOI":"10.1016\/j.blre.2020.100792","article-title":"Graft-versus-host disease prophylaxis: pathophysiology-based review on current approaches and future directions","volume":"48","author":"Martinez-Cibrian","year":"2021","journal-title":"Blood Rev"},{"issue":"2","key":"2025111014271243000_bib3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","article-title":"The Biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease","volume":"23","author":"Cooke","year":"2017","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"2025111014271243000_bib4","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3324\/haematol.2008.005017","article-title":"Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population","volume":"94","author":"Blanco","year":"2009","journal-title":"Haematologica"},{"issue":"3","key":"2025111014271243000_bib5","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1053\/j.seminhematol.2012.04.004","article-title":"Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience","volume":"49","author":"Moran","year":"2012","journal-title":"Semin Hematol"},{"issue":"9","key":"2025111014271243000_bib6","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1182\/blood-2005-05-2118","article-title":"Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines","volume":"107","author":"Blanco","year":"2006","journal-title":"Blood"},{"issue":"9","key":"2025111014271243000_bib7","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.3324\/haematol.2011.058677","article-title":"The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation","volume":"97","author":"Caballero-Vel\u00e1zquez","year":"2012","journal-title":"Haematologica"},{"key":"2025111014271243000_bib8","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/bjh.12410","article-title":"Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients","volume":"162","author":"Caballero-Vel\u00e1zquez","year":"2013","journal-title":"Br J Haematol"},{"issue":"11","key":"2025111014271243000_bib9","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.bbmt.2015.05.027","article-title":"A Bortezomib-based regimen offers promising survival and graft-versus-host disease prophylaxis in myeloablative HLA-mismatched and unrelated donor transplantation: a phase II trial","volume":"21","author":"Koreth","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"26","key":"2025111014271243000_bib10","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1200\/JCO.2012.42.0984","article-title":"Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation","volume":"30","author":"Koreth","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025111014271243000_bib11","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3324\/haematol.2017.176859","article-title":"Bortezomib-based immunosuppression after reduced intensity conditioning hematopoietic stem cell transplantation: randomized phase II results","volume":"103","author":"Koreth","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"2025111014271243000_bib12","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1038\/s41409-021-01452-1","article-title":"Delayed administration of ixazomib modifies the immune response and prevents chronic graft-versus-host disease","volume":"56","author":"Ramos","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"2025111014271243000_bib13","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1182\/blood-2014-02-554279","article-title":"Treatment of chronic graft-versus-host disease with bortezomib","volume":"124","author":"Pai","year":"2014  4","journal-title":"Blood"},{"issue":"12","key":"2025111014271243000_bib14","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1182\/blood-2012-11-465583","article-title":"Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease","volume":"121","author":"Inamoto","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2025111014271243000_bib15","doi-asserted-by":"publisher","first-page":"e89798","DOI":"10.1172\/jci.insight.89798","article-title":"An early-biomarker algorithm predicts lethal graft-versus-host disease and survival","volume":"2","author":"Hartwell","year":"2017","journal-title":"JCI insight"},{"issue":"10","key":"2025111014271243000_bib16","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1182\/blood-2006-11-055756","article-title":"Nonredundant roles for Stat5a\/b in directly regulating Foxp3","volume":"109","author":"Yao","year":"2007","journal-title":"Blood"},{"key":"2025111014271243000_bib17","doi-asserted-by":"publisher","first-page":"760199","DOI":"10.3389\/fimmu.2021.760199","article-title":"Kinase inhibition as treatment for acute and chronic graft- versus-host disease","volume":"12","author":"Braun","year":"2021","journal-title":"Front Immunol"},{"issue":"suppl 15","key":"2025111014271243000_bib18","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1016\/j.ejca.2013.03.024","article-title":"A drug-drug interaction study between the strong CYP3A4 inhibitor ketoconazole (keto) and ixazomib citrate (MLN9708), an investigational, orally active proteasome inhibitor, in patients with advanced solid tumors or lymphoma","volume":"31","author":"Gupta","year":"2013","journal-title":"J Clin Oncol"},{"key":"2025111014271243000_bib19","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"2025111014271243000_bib20","doi-asserted-by":"publisher","first-page":"e0125373","DOI":"10.1371\/journal.pone.0125373","article-title":"Quantifying distribution of flow cytometric TCR-V\u03b2 usage with economic statistics","volume":"10","author":"Van Der Geest","year":"2015","journal-title":"PLoS One"},{"issue":"suppl 1","key":"2025111014271243000_bib21","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood-2023-180142","article-title":"Effective prevention of steroid-requiring chronic graft-vs.-host disease with B cell depletion: a randomized, placebo-controlled trial","volume":"142","author":"Cutler","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2025111014271243000_bib22","first-page":"920.e1","article-title":"Oral proteasome inhibitor ixazomib for switch maintenance prophylaxis of recurrent or late acute and chronic graft-versus-host disease after day 100 in allogeneic stem cell transplantation","volume":"27","author":"Rodriguez","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"10","key":"2025111014271243000_bib23","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.bbmt.2020.07.005","article-title":"Ixazomib for chronic graft-versus-host disease prophylaxis following allogeneic hematopoietic cell transplantation","volume":"26","author":"Chhabra","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"2025111014271243000_bib24","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1016\/S2352-3026(19)30088-2","article-title":"Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial","volume":"6","author":"Sandmaier","year":"2019","journal-title":"Lancet Haematol"},{"issue":"25","key":"2025111014271243000_bib25","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"2025111014271243000_bib26","first-page":"v204.e1","article-title":"Post-transplantation cyclophosphamide after HLA identical compared to haploidentical donor transplant in acute myeloid leukemia: a study on behalf of GETH-TC","volume":"28","author":"Bail\u00e9n","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"10","key":"2025111014271243000_bib27","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1182\/bloodadvances.2024014879","article-title":"Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation","volume":"9","author":"Hyder","year":"2025","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2025111014271243000_bib28","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1182\/blood-2023-189430","article-title":"Phase I\/II Study of reduced dosing of post-transplantation cyclophosphamide (PTCy) after HLA-identical peripheral blood hematopoietic stem cell transplantation","volume":"142","author":"Zhang","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2025111014271243000_bib29","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1038\/s41409-024-02405-0","article-title":"Lower-dose post-transplant cyclophosphamide in haploidentical hematopoietic cell transplantation","volume":"59","author":"Fuji","year":"2024","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"2025111014271243000_bib30","first-page":"536.e1","article-title":"Outcomes of antithymocyte globulin-post-transplantation cyclophosphamide-cyclosporine-based versus antithymocyte globulin-based prophylaxis for 10\/10 HLA-matched unrelated donor allogeneic hematopoietic cell transplantation","volume":"30","author":"Salas","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"13","key":"2025111014271243000_bib31","doi-asserted-by":"crossref","first-page":"5254","DOI":"10.1182\/blood-2008-03-147322","article-title":"STAT-3 and ERK 1\/2 phosphorylation are critical for T-cell alloactivation and graft-versus-host disease","volume":"112","author":"Lu","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2025111014271243000_bib32","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1046\/j.1523-1747.2002.01719.x","article-title":"Role of p38 MAPK in transforming growth factor beta stimulation of collagen production by scleroderma and healthy dermal fibroblasts","volume":"118","author":"Sato","year":"2002","journal-title":"J Invest Dermatol"},{"issue":"4","key":"2025111014271243000_bib33","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ajpath.2016.12.016","article-title":"Blockade of p38 mitogen-activated protein kinase inhibits murine sclerodermatous chronic graft-versus-host disease","volume":"187","author":"Matsushita","year":"2017","journal-title":"Am J Pathol"},{"issue":"2","key":"2025111014271243000_bib34","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood.V98.2.489","article-title":"Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation","volume":"98","author":"Storek","year":"2001","journal-title":"Blood"},{"issue":"13","key":"2025111014271243000_bib35","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1182\/blood-2014-04-571125","article-title":"Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD","volume":"124","author":"Khoder","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2025111014271243000_bib36","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.exphem.2005.01.005","article-title":"B lymphocyte reconstitution after hematopoietic stem cell transplantation: functional immaturity and slow recovery of memory CD27+ B cells","volume":"33","author":"Avanzini","year":"2005","journal-title":"Exp Hematol"},{"issue":"2","key":"2025111014271243000_bib37","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.bbmt.2007.10.009","article-title":"Elevated numbers of immature\/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease","volume":"14","author":"Greinix","year":"2008","journal-title":"Biol Blood Marrow Transpl"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/21\/5528\/2418737\/blooda_adv-2025-016284-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/21\/5528\/2418737\/blooda_adv-2025-016284-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T19:27:20Z","timestamp":1762802840000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/21\/5528\/546411\/Ixazomib-decreases-the-risk-of-chronic-graft"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":37,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2025,11,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016284","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,11]]},"published":{"date-parts":[[2025,10,31]]}}}